GlaxoSmithKline PLC Company Leadership
| GSK Stock | USD 33.70 0.26 0.77% |
GlaxoSmithKline PLC employs about 70.2 K people. The company is managed by 34 executives with a total tenure of roughly 194 years, averaging almost 5.0 years of service per executive, having 2065.06 employees per reported executive. Inspection of GlaxoSmithKline PLC's management performance can provide insight into the company performance.
| Emma Walmsley CEO Chief Executive Officer, Executive Director |
| Brian McNamara CEO Chief Executive Officer - GSK Consumer Healthcare |
GlaxoSmithKline |
GlaxoSmithKline PLC's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with GlaxoSmithKline PLC's future performance. Based on our forecasts, it is anticipated that GlaxoSmithKline will maintain a workforce of about 70210 employees by December 2024.GlaxoSmithKline PLC's latest congressional trading
Congressional trading in companies like GlaxoSmithKline PLC ADR, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in GlaxoSmithKline PLC by those in governmental positions are based on the same information available to the general public.
| 2023-11-16 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-11-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify |
GlaxoSmithKline PLC Management Team Effectiveness
The company has Return on Asset of 0.0724 % which means that on every $100 spent on assets, it made $0.0724 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2185 %, implying that it generated $0.2185 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlaxoSmithKline PLC's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 0.15 this year, although the value of Return On Capital Employed will most likely fall to 0.17. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B.Common Stock Shares Outstanding is expected to rise to about 4.3 B this year. Net Income Applicable To Common Shares is expected to rise to about 14.1 B this year
GlaxoSmithKline PLC Workforce Comparison
GlaxoSmithKline PLC ADR is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 764,140. GlaxoSmithKline PLC holds roughly 70,212 in number of employees claiming about 9% of equities under Health Care industry.
GlaxoSmithKline PLC Profit Margins
The company has Net Profit Margin of 0.08 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.08 %, which entails that for every 100 dollars of revenue, it generated $0.08 of operating income.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.79 | 0.7007 |
|
| |||||
| Net Profit Margin | 0.22 | 0.1625 |
|
| |||||
| Operating Profit Margin | 0.32 | 0.2224 |
|
| |||||
| Pretax Profit Margin | 0.31 | 0.1999 |
|
| |||||
| Return On Assets | 0.15 | 0.0835 |
|
|
GlaxoSmithKline PLC ADR Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. GlaxoSmithKline PLC ADR Price Series Summation is a cross summation of GlaxoSmithKline PLC price series and its benchmark/peer.
GlaxoSmithKline PLC Notable Stakeholders
A GlaxoSmithKline PLC stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as GlaxoSmithKline PLC often face trade-offs trying to please all of them. GlaxoSmithKline PLC's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting GlaxoSmithKline PLC's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Emma Walmsley | Chief Executive Officer, Executive Director | Profile | |
| Brian McNamara | Chief Executive Officer - GSK Consumer Healthcare | Profile | |
| Deborah Waterhouse | Chief Executive Officer - ViiV Healthcare | Profile | |
| Luke Miels | President - Global Pharmaceuticals | Profile | |
| Hal Barron | Chief Scientific Officer, President - Research & Development, Executive Director | Profile | |
| CA BSc | President Development | Profile | |
| Philip Thomson | President Affairs | Profile | |
| Roger Connor | President - Global Manufacturing & Supply | Profile | |
| Phil Thomson | Senior Vice President - Global Communications | Profile | |
| Nick Hirons | Senior Vice President - Global Ethics and Compliance | Profile | |
| James Ford | Senior Vice President, Group General Counsel, Legal and Compliance | Profile | |
| Regis Simard | President - Pharmaceutical Supply Chain | Profile | |
| Lynn Elsenhans | Independent Non-Executive Director | Profile | |
| Harry Dietz | Non-Executive Independent Director, Scientific and Medical Expert | Profile | |
| Charles Bancroft | Non-Executive Independent Director | Profile | |
| Vivienne Cox | Independent Non-Executive Director and Workforce Engagement Director | Profile | |
| Judy Lewent | Non-Executive Independent Director | Profile | |
| Urs Rohner | Non-Executive Independent Director | Profile | |
| Marvinder Banga | Senior Non-Executive Independent Director | Profile | |
| Jesse Goodman | Non-Executive Independent Director and Scientific and Medical Expert | Profile | |
| Laurie Glimcher | Non-Executive Independent Director and Scientific & Medical Expert | Profile | |
| Julie ACA | CFO Director | Profile | |
| Iain Mackay | Chief Financial Officer, Executive Director | Profile | |
| Diana Conrad | Senior Vice President - Human Resources | Profile | |
| Shobie Ramakrishnan | Chief Digital and Technology Officer | Profile | |
| Sarah EltonFarr | Head Relations | Profile | |
| Julie Brown | Chief Officer | Profile | |
| Anne Beal | Non-Executive Independent Director | Profile | |
| Sally Jackson | Senior Vice President - Global Communications and CEO Office | Profile | |
| Victoria Whyte | Company Secretary | Profile | |
| Tony Wood | Chief Scientific Officer - Designate | Profile | |
| David Redfern | Chief Strategy Officer | Profile | |
| Jonathan Symonds | Independent Non-Executive Chairman of the Board | Profile | |
| Karenann Terrell | Chief Digital and Technology Officer | Profile |
About GlaxoSmithKline PLC Management Performance
The success or failure of an entity such as GlaxoSmithKline PLC ADR often depends on how effective the management is. GlaxoSmithKline PLC management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GlaxoSmithKline management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GlaxoSmithKline management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.19 | |
| Return On Capital Employed | 0.18 | 0.17 | |
| Return On Assets | 0.08 | 0.15 | |
| Return On Equity | 0.37 | 0.47 |
GlaxoSmithKline PLC Workforce Analysis
Traditionally, organizations such as GlaxoSmithKline PLC use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare GlaxoSmithKline PLC within its industry.GlaxoSmithKline PLC Manpower Efficiency
Return on GlaxoSmithKline PLC Manpower
| Revenue Per Employee | 431.9K | |
| Revenue Per Executive | 892M | |
| Net Income Per Employee | 70.2K | |
| Net Income Per Executive | 144.9M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.53 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.